Literature DB >> 19912091

"Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure.

Daniel P O'Brien1, Michael E Robson, Peter P Callan, Anthony H McDonald.   

Abstract

We present the first clinical descriptions of immune-mediated paradoxical reactions to effective antibiotic treatment for Mycobacterium ulcerans infection, which result in clinical deterioration after initial improvement. Recognition of this phenomenon could prevent unnecessary changes to antibiotic regimens, and might obviate the need for, or reduce the extent of, further surgery.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19912091

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  38 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Establishment of quantitative PCR (qPCR) and culture laboratory facilities in a field hospital in benin: 1-year results.

Authors:  Estelle Marion; Line Ganlonon; Eric Claco; Simon Blanchard; Marie Kempf; Ambroise Adeye; Annick Chauty
Journal:  J Clin Microbiol       Date:  2014-10-15       Impact factor: 5.948

3.  Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.

Authors:  Ghislain Emmanuel Sopoh; Ange Dodji Dossou; Luc Valère Brun; Yves Thierry Barogui; Jean Gabin Houézo; Dissou Affolabi; Séverin Y Anagonou; Roch Christian Johnson; Luc Kestens; Françoise Portaels
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

Review 4.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

5.  Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.

Authors:  Daniel P O'Brien; N Deborah Friedman; Aaron Walton; Andrew Hughes; Eugene Athan
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).

Authors:  Kapay Kibadi; Marleen Boelaert; Alexandra G Fraga; Makanzu Kayinua; Adhemar Longatto-Filho; Jean-Bedel Minuku; Jean-Baptiste Mputu-Yamba; Jean-Jacques Muyembe-Tamfum; Jorge Pedrosa; Jean-Jacques Roux; Wayne M Meyers; Françoise Portaels
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

7.  Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.

Authors:  N Deborah Friedman; Eugene Athan; Aaron L Walton; Daniel P O'Brien
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans.

Authors:  N Deborah Friedman; Anthony H McDonald; Michael E Robson; Daniel P O'Brien
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

Review 9.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

10.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.